Avanos Medical Inc

The Avanos Medical share rose to a 52-week high of $24.72 and gained about 97% over the past year; year-to-date the increase is over 120%. American Industrial Partners is offering a cash acquisition of roughly $1.27 billion and will pay shareholders $25.00 per share, representing a premium of about 72.1% to the last closing price. The company raises the long-term bonus target for CEO David C. Pacitti and proposes two new independent directors; Citizens reaffirms its rating at "Market Perform." » More on de.investing.com

American Industrial Partners will acquire Avanos Medical in an all-cash transaction at $25.00 per share, implying an enterprise value of about $1.272 billion. The purchase price is roughly 72.1% above the April 13 closing price and 82.8% above the volume-weighted 30-day average. The acquisition was unanimously approved by the board, is subject to customary conditions, and is expected to close in the second half of 2026. Upon closing, Avanos will become private and the common stock will be delisted from the NYSE; the transaction is not subject to a financing condition. » More on de.investing.com

Avanos Medical’s board raised the target value of the CEO David C. Pacitti’s annual long-term variable compensation under the 2021 Long Term Incentive Plan from $5.0 million to $5.5 million starting in 2026. The company reported strong Q4 2025 results (EPS $0.29, revenue $180.9 million) and plans to nominate two independent directors for the 2026 vote. Analysts expect a return to profitability in 2026, and Citizens rates the stock as “Market Perform.” » More on de.investing.com